Summary AOD-9604 is a compact, well-studied growth hormone fragment with a narrow lipolytic mechanism, a strong safety record in toxicology studies, and a clear position in metabolic research as a GH-receptor-independent tool compound
It targets an entirely different set of neurons in the brain, creating what researchers call complementary satiety signaling
Several licensed options are currently available in the UK, including semaglutide 2.4 mg (Wegovy), tirzepatide (Mounjaro), orlistat, liraglutide 3 mg (Saxenda), and naltrexone/bupropion (Mysimba)
They're shockingly effective, with a surprisingly low side effect profile, so much so that some people are left waiting for the other shoe to drop
In the gut microbiome, these beneficial bacteria ferment the fiber in your food and produce postbiotic metabolites such as butyrate
This timeline is based on the normal pace of Phase 3 data analysis, regulatory submission preparation, and FDA review processes